Ladenburg Thalmann Financial Services
http://www.ladenburg.comLadenburg Thalmann Financial Services, Inc. (AMEX: LTS) provides retail and institutional securities brokerage, investment banking, investment activities, and asset management services as well as equity research. In May of 2008, Ladenburg Thalmann acquired Punk Ziegel & Company to strengthen its trading, research, and investment banking departments. Ladenburg Thalmann is headquartered in Miami, FL.
View Older Stories View More Recent Stories
-
Ladenburg Thalmann Announces Closing of Public Offering of 7.25% Senior Notes Due 2028
-
Dolphin Entertainment (DLPN) PT Lowered to $7 at Ladenburg Thalmann
-
Ladenburg Thalmann Starts AcelRx Pharmaceuticals (ACRX) at Buy
-
Ladenburg Thalmann Starts Oasis Midstream Partners (OMP) at Buy
-
Ladenburg Launches New Succession, Continuity & Acquisitions Platform to Support Business Strategies of Financial Advisors
-
Form 13F-NT Ladenburg Thalmann Asset For: Jun 30
-
Form 13F-HR LADENBURG THALMANN FINAN For: Jun 30
-
Gladstone Investment Corporation Prices Series E Term Preferred Stock Offering
-
Gladstone Investment Corporation Prices Series E Term Preferred Stock Offering
-
RedHill Biopharma Announces Closing of $25 Million Underwritten Offering
-
RedHill Biopharma Announces Closing of $25 Million Underwritten Offering
-
FTJ FundChoice to Host 29 Financial Advisor Education Events Across the Country in a 2 Month Period
-
Gladstone Investment Corporation Launches New Series E Term Preferred Stock Offering
-
Gladstone Investment Corporation Launches New Series E Term Preferred Stock Offering
-
Ladenburg Thalmann Mourns Passing of Board Member Jeffrey S. Podell
-
Form 424B5 LADENBURG THALMANN FINAN
-
PennantPark Investment (PNNT) PT Raised to $8.50 at Ladenburg Thalmann
-
Form 8-K LADENBURG THALMANN FINAN For: Aug 09
-
Synalloy (SYNL) Announces At-The-Market Offering Program of Up to $10 Million
-
Synalloy Announces At-The-Market Offering Program
-
SCYNEXIS (SCYX) PT Lowered to $6 at Ladenburg Thalmann
-
Form FWP LADENBURG THALMANN FINAN Filed by: LADENBURG THALMANN FINANCIAL SERVICES INC.
-
Ladenburg Thalmann Announces Pricing of Public Offering of 7.25% Senior Notes Due 2028
-
TriplePoint Venture Growth BDC Corp. Closes Public Offering and Expects to Close Concurrent Private Placement of Common Stock
-
Ladenburg Thalmann Downgrades Neovasc (NVCN) to Neutral
-
Form 424B5 LADENBURG THALMANN FINAN
-
RedHill Biopharma (RDHL) Prices 4.17 Million Share Underwritten Offering at $6/ADS
-
RedHill Biopharma Announces Pricing of $25 Million Underwritten Offering
-
RedHill Biopharma Announces Pricing of $25 Million Underwritten Offering
-
Vaccinex Announces Pricing of Initial Public Offering
-
OvaScience (OVAS), Millendo Therapeutics Announce Merger
-
OvaScience and Millendo Therapeutics Announce Merger to Create Leading Rare Endocrine Disease Company
-
Ladenburg Thalmann Upgrades Comstock Resources (CRK) to Buy
-
AcelRx Pharmaceuticals Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
-
Form 8-K LADENBURG THALMANN FINAN For: Aug 07
-
Form 8-K LADENBURG THALMANN FINAN For: Aug 07
-
TriplePoint Venture Growth BDC (TPVG) Prices 6M Common Share Offering at $13.70/Sh
-
Form 10-Q LADENBURG THALMANN FINAN For: Jun 30
-
Ladenburg Reports Second Quarter 2018 Financial Results
-
Vericel Corporation (VCEL) PT Raised to $13.75 at Ladenburg Thalmann
-
TC Pipelines (TCP) PT Raised to $30 at Ladenburg Thalmann
-
Ladenburg Thalmann Downgrades Kindred Biosciences (KIN) to Neutral Citing Valuation
-
Energous Corp (WATT) PT Lowered to $24 at Ladenburg Thalmann
-
Ladenburg Downgrades New York Mortgage Trust (NYMT) to Neutral Citing Valuation
-
Ladenburg Thalmann Downgrades ReShape Lifesciences Inc (RSLS) to Neutral
-
BioTime, Inc. (BTX) PT Raised to $7 at Ladenburg Thalmann
-
Ladenburg Thalmann Starts Allena Pharmaceuticals (ALNA) at Buy
-
Ladenburg Thalmann Investment Banking Announces Successful Conclusion of Inaugural Technology Expo
-
Cellectar Biosciences Announces Closing of $16.56 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option
-
Cellectar Biosciences Announces Closing of $16.56 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option

